This document is an excerpt from the EUR-Lex website
Document 52018M9095
Prior notification of a concentration (Case M.9095 — UPL/Arysta LifeScience) (Text with EEA relevance.)
Prior notification of a concentration (Case M.9095 — UPL/Arysta LifeScience) (Text with EEA relevance.)
Prior notification of a concentration (Case M.9095 — UPL/Arysta LifeScience) (Text with EEA relevance.)
OJ C 454, 17.12.2018, p. 23–23
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
17.12.2018 |
EN |
Official Journal of the European Union |
C 454/23 |
Prior notification of a concentration
(Case M.9095 — UPL/Arysta LifeScience)
(Text with EEA relevance)
(2018/C 454/08)
1.
On 7 December 2018, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).This notification concerns the following undertakings:
|
— |
United Phosphorus Corporation Ltd, a wholly owned subsidiary of United Phosphorus Ltd (‘UPL’, India), |
|
— |
Arysta LifeScience Inc. (‘Arysta’, USA). |
UPL acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Arysta.
The concentration is accomplished by way of purchase of shares.
2.
The business activities of the undertakings concerned are:|
— |
UPL is active worldwide in the manufacture of products for the protection of plantations, intermediates, specialty chemicals and other industrial chemicals, including insecticides, fungicides, herbicides, fumigants, plant growth regulators and rodenticides, |
|
— |
Arysta is a global provider of innovative crop protection solutions, including bio-solutions and seed treatments. Arysta specialises in the development, formulation, registration, marketing and distribution of differentiated crop protection chemicals for a variety of crops and applications. |
3.
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.
4.
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:
M.9095 — UPL/Arysta LifeScience
Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:
|
Email: COMP-MERGER-REGISTRY@ec.europa.eu |
|
Fax +32 22964301 |
|
Postal address: |
|
European Commission |
|
Directorate-General for Competition |
|
Merger Registry |
|
1049 Bruxelles/Brussel |
|
BELGIQUE/BELGIË |
(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).